Pulmonary Vascular Dilatation Detected by Automated Transcranial Doppler in COVID-19 Pneumonia.

To the Editor:

Some patients with coronavirus disease (COVID-19) pneumonia demonstrate severe hypoxemia despite having near normal lung compliance, a combination not commonly seen in typical acute respiratory distress syndrome (ARDS) (1). The disconnect between gas exchange and lung mechanics in COVID-19 pneumonia has raised the question of whether the mechanisms of hypoxemia in COVID-19 pneumonia differ from those in classical ARDS. Dual-energy computed tomographic imaging has demonstrated pulmonary vessel dilatation (2) and autopsies have shown pulmonary capillary deformation (3) in patients with COVID-19 pneumonia.

Contrast-enhanced transcranial Doppler (TCD) of the bilateral middle cerebral arteries after the injection of agitated saline is an ultrasound technique, similar to transthoracic or transesophageal echocardiography, that can be performed to detect microbubbles and diagnose intracardiac or intrapulmonary shunt (Figure 1) (4, 5). TCD is more sensitive than transthoracic echocardiography in detecting right-to-left shunt, (6) and it is less invasive than transesophageal echocardiography. We performed a cross-sectional pilot study of TCD (Lucid Robotic System; NovaSignal Corp) in all mechanically ventilated patients with severe COVID-19 pneumonia from two COVID-19 ICUs who were not undergoing continuous renal replacement therapy or extracorporeal membrane oxygenation (N = 18). This study was approved by the Mount Sinai Institutional Review Board (approval 20–03660). Agitated saline was injected through either a peripheral intravenous line in the upper extremity or a central line in the internal jugular vein. The system software automatically counted the number of microbubbles detected over 20 seconds; as a quality control measure, we manually counted and confirmed the number of microbubbles and were blinded to the patients’ clinical condition and PaO:FiO ratio. Sixty-one percent (n = 11) of patients were men. Patients had a median age of 59 years (interquartile range, 54–68 years), with a PaO:FiO ratio of 127 mm Hg (interquartile range, 94–173 mm Hg). Lung compliance was measured in 16 patients and was low (median 22 ml/cm H2O; interquartile range 15–34 ml/cm H2O). None of the patients had a known history of chronic liver disease or preexisting intracardiac shunt. Contrast-enhanced TCD detected a median of 8 microbubbles (interquartile range, 1–22; range 0–300). Three major findings from contrast-enhanced TCD were observed. First, 15 of 18 (83%) patients had detectable microbubbles (see Figure 1 for representative images). Second, the PaO:FiO ratio was inversely correlated with the number of microbubbles (Pearson’s r = −0.55; P = 0.02) (Figure 2A). Third, the number of microbubbles was inversely correlated to lung compliance (Pearson’s r = −0.61; P = 0.01) (Figure 2B).

Figure 1.

Assessment of microbubbles by transcranial Doppler (TCD) after injection of agitated saline. Representative images were captured during TCD evaluation after injection of agitated saline. (A and B) Continuous spectral waveforms of the middle cerebral artery (MCA) during insonation over 5 seconds. C and D demonstrate the power M-mode, and positive microbubbles appear as vertical lines (arrows). (A and C) Images from the left MCA of a 60-year-old woman in whom TCD detected five microbubbles. (B and D) Images from the right MCA of a 69-year-old man in whom TCD detected 300 microbubbles. His PaO:FiO ratio was 55 mm Hg, which was the lowest in the cohort.

Figure 2.

Associations between number of microbubbles and PaO:FiO ratio and lung compliance. (A) A scatterplot of the log-transformed number of microbubbles as detected by transcranial Doppler and PaO:FiO ratio (r = −0.55; P = 0.02) and suggests that the number of microbubbles increases with declining PaO:FiO ratio. (B) A scatterplot of the log-transformed number of microbubbles as detected by transcranial Doppler and lung compliance (r = −0.61; P = 0.01) and suggests that the number of microbubbles increases with declining lung compliance.

These data suggest that pulmonary vasodilatations may explain the disproportionate hypoxemia in some patients with COVID-19 pneumonia and, somewhat surprisingly, track with poor lung compliance (1). Our detection of transpulmonary bubbles may be analogous to hepatopulmonary syndrome, a pulmonary vascular disorder of chronic liver disease characterized by pulmonary vascular dilatations with increased blood flow to affected lung units, which results in ventilation–perfusion mismatch and hypoxemia (4). The normal lung filters microbubbles from the injection of agitated saline as the bubble diameter is larger (smallest bubble approximately 24 μm in diameter [5]) than the normal pulmonary capillary (<15 μm in diameter [7]). In hepatopulmonary syndrome, and similar to what we observed in this pilot study, the presence and degree of transpulmonary bubble transit correlate with the degree of hypoxemia (8). Although we cannot rule out intracardiac shunt as a cause of observed microbubbles, we note that the prevalence of transpulmonary bubbles seen in our study is markedly higher than the prevalence of patent foramen ovales seen in the general population (9). In a prior study of 265 patients with ARDS receiving mechanical ventilation, only 42 patients (16%) were found to have patent foramen ovale as assessed by contrast transesophageal echocardiography (10).

Hypoxemia in ARDS is predominantly caused by right-to-left shunt, in which systemic venous blood flows to lung regions with collapsed and/or flooded alveoli and does not get oxygenated as it passes through the lung (11). Transpulmonary bubble transit has been detected in 26% of patients with classical ARDS, although neither their presence nor their severity correlates with oxygenation (10), implying that pulmonary vascular dilatations are not a major mechanism of hypoxemia in typical ARDS. In order for transpulmonary bubble transit to occur, pulmonary vascular dilatations or pulmonary arteriovenous malformations must be present; a lack of hypoxic vasoconstriction is not sufficient. Although these observations are preliminary, the correlation seen here between the degree of transpulmonary bubble transit and PaO:FiO ratio suggests that pulmonary vascular dilatation may be a significant cause of hypoxemia in patients with COVID-19 respiratory failure. Interestingly, patients with worse lung compliance demonstrated more microbubbles, which suggests that pulmonary vascular dilatation may worsen in parallel with the typical diffuse alveolar damage of ARDS.

Our understanding of the pathophysiology of hypoxemic respiratory in COVID-19 is limited. Although a larger, confirmatory study is needed, these data, in conjunction with recent radiographic and autopsy findings, seem to implicate pulmonary vascular dilatation as a cause of hypoxemia in patients with COVID-19 pneumonia.